Mark Ferguson, the CEO of the UK's Renovo Group, says the company is getting closer to a licensing deal for its lead product, an anti-scarring therapy. Renovo has gathered positive data on Juvista from four mid-stage trials and Ferguson expects to announce a partner for the program by April, the first anniversary of its IPO. Juvista is injected into wounds following surgery and the company's broker has touted the therapy as a potential blockbuster. Final data should be submitted in 2009 and Renovo also expects to keep to its timetable to file for approval of Zesteem in 2008.
- here's the AFX report on Renovo
ALSO: Renovo has released more positive data from one of its Phase II trials of Juvista. Report